Fendiline for carbapenem-resistant Acinetobacter baumannii

Antimicrobial resistance (AMR) is one of the greatest threats to modern medicine. Unfortunately, very few antibiotics currently in the development pipeline have novel mechanisms of action or unique chemical structures.

Most new agents are modifications of existing drug classes and remain vulnerable to established resistance mechanisms. This has raised concerns about a gradual return to a ‘pre-antibiotic era’, where routine infections and medical procedures become increasingly difficult.1

Among the most concerning is carbapenem-resistant Acinetobacter baumannii (CRAB), which is ranked as a critical priority pathogen by the World Health Organization (WHO) because of its virulence, resistance and limited treatment options. It is one of the top five pathogens responsible for deaths attributable to antibiotic-resistant infections worldwide.2

An opportunistic Gram-negative bacterium,1 CRAB causes severe hospital-acquired infections such as pneumonia – especially among patients in intensive care. Treatment requires expert advice, guided by local susceptibility data and the patient’s susceptibility testing results.3

Since the classification of CRAB as a critical pathogen in 2017, there have been no new drugs effective against these metallo-β-lactamase-producing CRAB strains, whose enzymes hydrolyse nearly all β-lactam antibiotics. This highlights the ongoing challenge and need for continued investment in research and development.

Novel screening strategies of existing drug libraries have made it easier to repurpose medicines, compared to traditional methods of testing assays against lab strains.1 For example, the WHO recommends developing small molecules that target OXA-type β-lactamases, which is often responsible for causing resistance in CRAB.2

One such candidate identified is fendiline, a calcium channel blocker originally developed for cardiovascular indications. Although not currently used as an antimicrobial, recent research suggests it may exploit vulnerabilities created by resistance mechanisms in CRAB.1 Fendiline was found to have increased antimicrobial activity against strains expressing OXA-23, a β-lactamase enzyme that is a major cause of carbapenem resistance. Interestingly, fendiline was more active against carbapenem-resistant bacteria than against antibiotic-susceptible strains.1

Genetic and proteomic analyses showed that fendiline inhibits the bacterial lipoprotein trafficking (Lol) pathway, an essential system responsible for transporting lipoproteins to the outer membrane, and other essential functions.1

The researchers demonstrated that OXA-23 itself is an outer membrane lipoprotein and concluded that overexpression of this resistance enzyme placed additional stress on the normal bacterial lipoprotein trafficking. As a result, carbapenem-resistant bacteria were more susceptible to fendiline-mediated inhibition of the Lol pathway.1

However, several limitations should be considered. The study was laboratory based and focused primarily on understanding the mechanism of action rather than evaluating clinical outcomes. Fendiline has not been studied for use in people with CRAB infections, and its clinical utility – including pharmacokinetics, optimal dosing and safety profile for antimicrobial use – remains uncertain. Further work is also needed to determine whether activity is maintained in vivo, and across diverse CRAB strains, and whether bacterial resistance to fendiline could develop.

Despite these limitations, the findings highlight a novel approach to antimicrobial drug discovery. Importantly, this study provides proof-of-concept that AMR mechanisms can create physiological weaknesses which may be therapeutically targeted. Rather than simply overcoming resistance, this strategy exploits the biological cost of resistance itself.

Future research is needed to evaluate fendiline and related compounds in animal and clinical studies to explore whether similar strategies can be applied to other multidrug-resistant pathogens. While fendiline is not ready for clinical use as an antimicrobial, this study demonstrates how repurposing existing medicines helps address the growing challenge of AMR.

In an era of limited antibiotic innovation, exploiting vulnerabilities created by resistance itself may provide a promising avenue for future antimicrobial development.

References

  1. Colquhoun JM, Brzezinski CU, Ji A, et al. Repurposing a drug to punish carbapenem-resistant Acinetobacter baumannii. Proc Natl Acad Sci U S A. 2025;122(24):e2423650122.
  2. World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. At: https://www.who.int/publications/i/item/9789240093461
  3. Antibiotic Health Expert Group. Acinetobacter baumannii pneumonia in adults. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2025. At: https://www.tg.org.au